Show simple item record

dc.contributor.authorCoombs, Geoffrey
dc.contributor.authorPearson, J.
dc.contributor.authorNimmo, G.
dc.contributor.authorCollignon, P.
dc.contributor.authorTurnidge, J.
dc.date.accessioned2017-01-30T15:21:52Z
dc.date.available2017-01-30T15:21:52Z
dc.date.created2014-02-25T20:00:38Z
dc.date.issued2013
dc.identifier.citationCoombs, Geoffrey W. and Pearson, Julie C. and Nimmo, Graeme R. and Collignon, Peter J. and Bell, Jan M. and McLaws, Mary-Louise and Christiansen, Keryn J. and Turnidge, John D. 2013. Antimicrobial susceptibility of Staphylococcus aureus and molecular epidemiology of meticillin-resistant S. aureus isolated from Australian hospital inpatients: Report from the Australian Group on Antimicrobial Resistance 2011 Staphylococcus aureus Surveillance Programme. Journal of Global Antimicrobial Resistance. 1 (3): pp. 149-156.
dc.identifier.urihttp://hdl.handle.net/20.500.11937/45578
dc.identifier.doi10.1016/j.jgar.2013.04.005
dc.description.abstract

The Australian Group on Antimicrobial Resistance (AGAR) performs regular multicentre period prevalence studies to monitor changes in antimicrobial resistance. In 2011, 29 laboratories in Australia participated in the national surveillance of Staphylococcus aureus resistance. The survey only included unique isolates from clinical specimens collected ≥48 h after hospital admission. MRSA accounted for 30.3% of S. aureus isolates. MRSA resistance to ciprofloxacin, erythromycin, tetracycline, trimethoprim/sulfamethoxazole, gentamicin and clindamycin (constitutive resistance) varied considerably between regions. Resistance to non-β-lactam antimicrobials was uncommon in MSSA, with the exception of erythromycin. Regional variation in resistance was due to the differential distribution of MRSA clones between regions. The proportion of S. aureus genetically characterised as healthcare-associated MRSA (HA-MRSA) was significantly lower in this survey (18.2%) compared with the 2005 survey (24.2%) (P < 0.0001). Although four HA-MRSA clones were characterised, 98.8% of HA-MRSA were classified as either ST22-MRSA-IV [2B] (EMRSA-15) or ST239-MRSA-III [3A] (Aus-2/3 EMRSA). Multiclonal community-associated MRSA (CA-MRSA) increased markedly from 6.5% in 2005 to 11.7% of all S. aureus in 2011 (P < 0.0001). Although the proportion of MRSA resistant to non-β-lactam antimicrobials has decreased nationally, the proportion of S. aureus that are MRSA has remained stable. This is primarily due to non-multiresistant CA-MRSA becoming more common in Australian hospitals at the expense of the long-established multiresistant ST239-MRSA-III [3A] (Aus-2/3 EMRSA). Given hospital outbreaks of CA-MRSA are thought to be extremely rare, it is most likely that patients colonised at admission with CA-MRSA have become infected with the colonising strain during their hospital stay.

dc.publisherElsevier
dc.subjectMSSA
dc.subjectMRSA
dc.subjectHospital inpatients
dc.subjectPeriod prevalence studies
dc.subjectStaphylococcus aureus
dc.titleAntimicrobial susceptibility of Staphylococcus aureus and molecular epidemiology of meticillin-resistant S. aureus isolated from Australian hospital inpatients: Report from the Australian Group on Antimicrobial Resistance 2011 Staphylococcus aureus Surveillance Programme
dc.typeJournal Article
dcterms.source.startPage149
dcterms.source.endPage156
dcterms.source.issn2213-7165
dcterms.source.titleJournal of Global Antimicrobial Resistance
curtin.department
curtin.accessStatusFulltext not available


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record